Glaukos Corp (GKOS)
138.44
-0.18
(-0.13%)
USD |
NYSE |
Nov 15, 16:00
138.37
-0.07
(-0.05%)
After-Hours: 20:00
Glaukos Research and Development Expense (TTM): 136.96M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 136.96M |
| June 30, 2024 | 135.52M |
| March 31, 2024 | 134.32M |
| December 31, 2023 | 138.77M |
| September 30, 2023 | 137.52M |
| June 30, 2023 | 133.09M |
| March 31, 2023 | 131.56M |
| December 31, 2022 | 123.27M |
| September 30, 2022 | 114.14M |
| June 30, 2022 | 114.11M |
| March 31, 2022 | 106.66M |
| December 31, 2021 | 101.00M |
| September 30, 2021 | 95.56M |
| June 30, 2021 | 87.02M |
| March 31, 2021 | 81.74M |
| December 31, 2020 | 85.39M |
| September 30, 2020 | 84.18M |
| June 30, 2020 | 81.15M |
| March 31, 2020 | 79.25M |
| December 31, 2019 | 68.31M |
| Date | Value |
|---|---|
| September 30, 2019 | 61.23M |
| June 30, 2019 | 57.16M |
| March 31, 2019 | 52.70M |
| December 31, 2018 | 49.68M |
| September 30, 2018 | 47.24M |
| June 30, 2018 | 43.85M |
| March 31, 2018 | 40.87M |
| December 31, 2017 | 38.90M |
| September 30, 2017 | 35.78M |
| June 30, 2017 | 33.78M |
| March 31, 2017 | 31.10M |
| December 31, 2016 | 29.22M |
| September 30, 2016 | 28.12M |
| June 30, 2016 | 26.48M |
| March 31, 2016 | 26.87M |
| December 31, 2015 | 25.05M |
| September 30, 2015 | 24.06M |
| June 30, 2015 | 22.98M |
| March 31, 2015 | 20.06M |
| December 31, 2014 | 19.21M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
68.31M
Minimum
Dec 2019
138.77M
Maximum
Dec 2023
108.48M
Average
110.38M
Median
Research and Development Expense (TTM) Benchmarks
| Boston Scientific Corp | 1.519B |
| Baxter International Inc | 754.00M |
| Masimo Corp | 183.10M |
| Teleflex Inc | 152.98M |
| Perspective Therapeutics Inc | 28.53M |